2015
An update on the current pharmacotherapy for endometrial cancer
de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion On Pharmacotherapy 2015, 17: 489-499. PMID: 26629895, DOI: 10.1517/14656566.2016.1127351.Peer-Reviewed Original ResearchConceptsEndometrial cancerMainstay of treatmentCommon gynecologic malignancyCurrent conventional therapiesGynecologic malignanciesCurrent pharmacotherapyAvailable pharmacotherapiesConventional therapyCurrent therapiesEndometrial tumorsTargeted therapyImmunohistochemical characterizationRadiation therapyClinical careAggressive formNew therapiesPreclinical settingTherapyTherapeutic agentsCancerPharmacotherapyTumorsAvailable literatureHistoric treatmentTreatment
2013
Early stage uterine serous carcinoma: Management updates and genomic advances
Fader AN, Santin AD, Gehrig PA. Early stage uterine serous carcinoma: Management updates and genomic advances. Gynecologic Oncology 2013, 129: 244-250. PMID: 23321062, DOI: 10.1016/j.ygyno.2013.01.004.Peer-Reviewed Original ResearchConceptsEarly stage uterine serous carcinomaUterine serous carcinomaRisk of recurrenceResidual uterine diseaseTaxane-based chemotherapyEarly-stage diseaseNumber of patientsCancer-related deathHigh recurrence rateOptimal management approachHER2/neuPotential therapeutic targetAvailable literaturePIK3CA/Adjuvant therapyCervical involvementStage diseaseBiologic therapyProspective trialEndometrial cancerProspective studyRecurrence rateSerous carcinomaSurvival outcomesAggressive subtype